LC-Plasma-based Vaccine Research Selected for SCARDA Project
May 07 2024 - 10:00PM
Business Wire
- Towards the Development of a Vaccine to
prevent Respiratory Virus Infection -
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and
National Institute of Infectious Diseases (NIID) are jointly
conducting studies to investigate the protective efficacy of L.
lactis strain Plasma [postbiotic] (LC-Plasma) immunization against
infectious diseases. We now announce that a proposal for our
collaborative research has currently been accepted as a project for
research and development into new modalities contributing to
vaccine development by the Strategic Center of Biomedical Advanced
Vaccine Research and Development for Preparedness and Response
(SCARDA) in the Japan Agency for Medical Research and Development
(AMED).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240507111790/en/
●
Information on the Research
Project
Title: Development of an intranasal
Lactococcus lactis strain Plasma vaccine inducing innate memory
Representative: Tetsuro Matano, Deputy
Director-General, NIID
Representative: Daisuke Fujiwara,
Executive Officer, General Manager, Health Science Institute, Kirin
Holdings
●
Unique point This research aims at
developing an intranasal LC-Plasma vaccine to induce innate
immunity for prevention of respiratory virus infection.
Backgrounds SCARDA was established at AMED in March,
2022, based on the national strategy, to strengthen strategic
research funding and to promote the formation of world-class
research and development centers
(https://www.amed.go.jp/en/program/list/21/index.html). SCARDA is
supporting Research & Development for new generation vaccines.
Traditional vaccines are expected to induce adaptive immune
responses including antibody and T cell responses to prevent
infection with pathogens such as viruses and bacteria. Recently,
the concept of trained immunity has been discussed and there have
been several attempts to develop vaccines inducing effective innate
responses against infectious diseases, which has not yet been
achieved.
LC-Plasma is characterized by its ability to activate
plasmacytoid dendritic cells (pDCs) and stimulate interferon
production, leading to enhancement of innate immune responses.
Through joint research with NIID, Kirin Holdings has confirmed that
SARS-CoV-2 replication is inhibited by the culture supernatants of
pDCs stimulated with LC-Plasma (Ishii et al, BBRC 662:26,
2023).
Kirin Holdings and NIID are now conducting collaborative
research for the development of vaccines inducing innate immune
responses against respiratory virus infection by utilizing
LC-Plasma for medical use. This project is to explore the potential
of intranasal LC-Plasma vaccination to prevent respiratory
infection with viruses including SARS-CoV-2 and influenza
viruses.
About Kirin Holdings
Kirin Holdings Company, Limited is an international company that
operates in the Food & Beverages domain (Food & Beverages
businesses), Pharmaceuticals domain (Pharmaceuticals businesses),
and Health Science domain (Health Science business), both in Japan
and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was
established in 1885. Japan Brewery became Kirin Brewery in 1907.
Since then, the company expanded its business with fermentation and
biotechnology as its core technologies, and entered the
pharmaceutical business in the 1980s, all of which continue to be
global growth centers. In 2007, Kirin Holdings was established as a
pure holding company and is currently focusing on boosting its
Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term
management plan launched in 2019, the Kirin Group aims to become A
global leader in CSV*, creating value across our world of Food
& Beverages to Pharmaceuticals. Going forward, the Kirin Group
will continue to leverage its strengths to create both social and
economic value through its businesses, with the aim of achieving
sustainable growth in corporate value.
* Creating Shared Value. Combined added value for consumers as
well as for society at large.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507111790/en/
Press Contact Corporate Communication Department Kirin Holdings
Company, Limited Nakano Central Park South, 4-10-2 Nakano,
Nakano-ku, Tokyo +81-3-6837-7028 https://www.kirinholdings.com/en/
kirin-cc@kirin.co.jp
National Institute of Infectious Diseases Contact 1-23-1 Toyama,
Shinjuku-ku, Tokyo +81-3-5285-1111 info@nih.go.jp